The effects of Japan’s National Action Plan on Antimicrobial Resistance on antimicrobial use

International Journal of Infectious Diseases

Shinya Tsuzuki¹  Yuichi Muraki²  Yoshiki Kusama³  Norio Ohmagari³  Ryuji Koizumi³  Masahiro Ishikane⁴ 

[1] Collaborative Chairs Emerging and Reemerging Infectious Diseases, National Center for Global Health and Medicine, Graduate School of Medicine, 1-1, Seriryo-tyo, Aoba-ku, Sendai, Miyagi, Japan;Corresponding author at: AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.;AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, Japan;Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University, 5, Nakauchi-machi, Misasagi, Yamashina-ku, Kyoto-shi, Kyoto, Japan;

关键词: Antimicrobial use;    National action plan;    Antimicrobial resistance;    Interrupted time-series analysis;   

DOI  :  

来源: DOAJ

【 摘 要 】

The aim of this study was to estimate the effects of Japan’s National Action Plan on Antimicrobial Resistance 2016–2020 (NAP) on antimicrobial use (AMU). Monthly AMU from January 2013 to December 2019 was calculated using sales data, and time-series charts of AMU were then created for the total antimicrobials and target drug categories shown in the NAP (oral cephalosporins, oral fluoroquinolones, oral macrolides, and parenteral antimicrobials). Twelve-month predictions were generated to evaluate AMU in 2020. The publication of the NAP was associated with an AMU reduction in total antimicrobials, cephalosporins, fluoroquinolones, and macrolides. Parenteral AMU showed an upward trend, although it was not significantly associated with the intervention effect. AMU reductions of 15.0% for total antimicrobials, 26.3% for cephalosporins, 23.5% for fluoroquinolones, and 24.6% for macrolides were predicted for 2020 relative to 2013. However, there was a predicted increase of 17.4% for parenteral AMU. While Japan’s NAP has contributed to the reduction in national AMU over the past 5 years, sustained action is still needed to further improve antimicrobial stewardship and promote countermeasures to antimicrobial resistance.

【 授权许可】

Unknown